Motif Neurotech Receives FDA Approval for Clinical Trial of BCI for Depression
Motif Neurotech has announced that the FDA has approved an Investigational Device Exemption, allowing the company to begin its RESONATE Early Feasibility Study, which involves the first clinical trial of its therapeutic brain-computer interface (BCI) aimed at treating treatment-resistant depression.
HOUSTON–(BUSINESS WIRE)–Motif Neurotech announced that the FDA has approved an Investigational Device Exemption for their RESONATE Early Feasibility Study.